• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

piers.blombery@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-9902-0022

A/Prof Piers Blombery

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

259 Scholarly works
6 Projects

HIGHLIGHTS

  • 2024

    Research grants (ARC, NHMRC, MRFF)

    ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)
  • 2023

    Journal article

    Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
    DOI: 10.1182/blood.2022016090
  • 2022

    Journal article

    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
    DOI: 10.1182/blood.2022016040
  • 2022

    Journal article

    Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
    DOI: 10.1182/bloodadvances.2022008325
  • 2022

    Journal article

    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
    DOI: 10.1182/blood.2021012775
  • 2022

    Research grants (ARC, NHMRC, MRFF)

    Understanding and Averting Blood Cancer Resistance to Therapy
  • 2021

    Research grants (ARC, NHMRC, MRFF)

    INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-Emptive Therapy in AML): A Multi-Arm, Precision-Based, Recursive, Platform Trial
Piers Blombery

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    T-ALL: the origin story
    DOI: 10.1182/blood.2025032944
  • 2026

    Journal article

    MPL W515R hereditary thrombocytosis associated with a benign long-term clinical course
    DOI: 10.1016/j.pathol.2025.12.010
  • 2026

    Journal article

    HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma
    DOI: 10.1111/bjh.70478
  • 2026

    Journal article

    Activating somatic EPOR mutation in primary erythrocytosis
    DOI: 10.1016/j.pathol.2026.04.005
  • 2026

    Journal article

    Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study
    DOI: 10.1002/hem3.70386
  • 2026

    Journal article

    The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia
    DOI: 10.1182/blood.2025029905
  • 2026

    Journal article

    Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
    DOI: 10.1182/bloodadvances.2025016646
  • 2026

    Journal article

    Refinement of the classification of DDX41 variants through analysis of aggregated clinical datasets
    DOI: 10.1038/s41375-026-02886-6

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224